Infection by Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in infants. The currently available preventive treatment is a monthly injection with an anti-RSV antibody, which is only given to high-risk infants and only temporarily provides protection due to a limited half-life. Now, a new antibody against RSV, which was developed by scientists of Amsterdam UMC spin-off AIMM Therapeutics, has come one step closer to market authorization, showing positive results in a Phase III clinical trial performed by pharma companies Astra Zeneca and Sanofi. This antibody, being more stable than the existing antibody, will only need to be administered once per RSV-season and should become available to all infants.
For more information click here.
Photo credit: Respiratory syncytial virus (RSV) infection – Case 288 by Yale Rosen. Photo is cropped.
UvA Ventures Holding has launched the Social Sciences & Humanities (SSH) Impact Fund that aims to capitalize on SSH research by supporting the development of academic spin-offs that address societal challenges. The initiative is a response to the need for practical applications of SSH research, identified through discussions with university researchers. For whom? The SSH […]
News“With this agreement, we fortify our collaboration, reaffirming our dedication to diversity, sustainability, and entrepreneurship – values exemplified by DNNL. An endeavor that aligns with the educational and research efforts we stand for as a university,” says VU President Jonkman.
NewsKepler Vision Technologies, a spin-off company from the University of Amsterdam, secured a significant €1.5M investment from ROM InWest last month. The Dutch company will use the funds to accelerate the production of its ‘Kepler Night Nurse’ solution, a smart technology for care home fall detection. The company is now positioned for global expansion, targeting the UK and US markets.
News